Clinical Trials Directory

Trials / Unknown

UnknownNCT03744130

Contrast-enhanced Bowel Ultrasound in Making a Diagnosis and Follow-up of Patients With Inflammatory Bowel Disease

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
200 (estimated)
Sponsor
State Scientific Centre of Coloproctology, Russian Federation · Other Government
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine the efficacy of SonoVue® in participants with Crohn's disease and ulcerative colitis to various aspects including type of Inflammatory Bowel Disease, disease activity, the need for surgical treatment.

Detailed description

Each patient is subjected to clinical, laboratory and endoscopic evaluation, each eligible patient is assigned to one of the arms: Arm 1: patients with ulcerative colitis (50 patients) Arm 2: patients with Crohn's disease (50 patients) In each arm, patients are classified according to clinical an endoscopic activity of the disease. Each patient is subjected to ultrasound examination of the bowel using a Philips iU 22 machine according to a standardized protocol: * 12h fasting period * exploratory scanning with the use of convex C5-1 probe * detailed scanning with the use of linear L 12-5 probe with Power Doppler * choosing a bowel segment with the most prominent changes * Contrast-enhanced Ultrasound (CEUS) CEUS is performed according to the following protocol: * administration of drotaverine hydrochloride (No-Spa ®) to reduse excessive peristaltic movement * visualization of the previously chosen affected bowel segment with the use of DCE-US (Dynamic Contrast-Enhanced Ultrasound) technology * administration of 2.4 ml SonoVue® intravenously with a bolus injection through a peripheric venous line (left antecubital vein), followed by a 10ml 0.9% Natrium Chloride bolus * the video-loop is acquired during contrast agent administration and wash-out (preferable loop duration - 3 min) * the original DICOM loop is sent to a work station Philips QLab platform is used to acquire a fitted Local Density Random Walk Wash-in Wash-out algorithm (LDRWIWO algorhithm) time-intensity curve of contrast agent wash-in and wash-out. Qualitative and quantitative (Time to peak, Rise time, Mean transit time, Wash-in Slope, Peak intensity, Area under curve, Time from peak to one half) parameters are calculated for each region of interest (ROI).

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTContrast-enhanced Ultrasound1. administration of drotaverine hydrochloride (No-Spa ®) to reduse excessive peristaltic movement 2. visualization of the previously chosen affected bowel segment with the use of DCE-US (Dynamic Contrast-Enhanced Ultrasound) technology 3. administration of 2.4 ml SonoVue® intravenously with a bolus injection through a peripheric venous line (left antecubital vein), followed by a 10ml 0.9% Natrium Chloride bolus 4. the video-loop is acquired during contrast agent administration and wash-out (preferable loop duration - 3 min) 5. the original DICOM loop is sent to a work station

Timeline

Start date
2018-01-10
Primary completion
2020-12-30
Completion
2021-06-30
First posted
2018-11-16
Last updated
2018-11-23

Locations

1 site across 1 country: Russia

Source: ClinicalTrials.gov record NCT03744130. Inclusion in this directory is not an endorsement.